Oncotarget Has Been Very Impactful in the Growth of Science and the Lives of Many

Oncotarget is a free to access online medical journal that is published weekly by Impact Journals. It can also be available in print upon special arrangements. The journal has been in existence since the year 2010. It was established to provide science discoveries on oncology to its readers. Renowned Scientist and former oncology professor, Mikhail Blagosklonny, and a college professor and cancer researcher, Andrei V. Gudkov, serve as the chief editors. The Gordon Research Conference is the Oncotarget’s sponsor.

What makes it Unique

Oncotarget has continued to grow in popularity. In the recent past, scientific discoveries have been on the rise. People would, however, not know about these discoveries if they are not placed at an accessible point. Oncotarget aims at reaching the highest number of people with these findings. The results are peer-reviewed, which makes them more grounded for the users. Much impact is achieved by the timely information conveyed through the journal. By providing information full of insight, many people have continued to embrace the journal. Visit Oncotarget’s profile page at Facebook.

Going Beyond Oncology

Despite the initial strategy being a focus on oncology only, Oncotarget has grown to accept other parts of science. They include Neuroscience, Metabolism, Endocrinology, Cardiology, Cell Biology, and Pharmacology. More participants have been incorporated in the journal through the acceptance of other areas of science, which creates more impact. It has also made Oncotarget a one stop platform for people looking for information about different illnesses. Through linking various fields of science, Oncotarget has been able to bridge the gap between biomedical sciences. It has also optimized the use of basic and clinical sciences in preventing and treating diseases. By contributing to the advancement science, Oncotarget is on the way to achieving its mission of a life free of diseases.

Follow: https://twitter.com/oncotargetjrnl?lang=en


Oncotarget has changed the lives of many. By using the information in the journal, patients have been able to manage existing diseases and consequently enjoy longer lives. The impressive performance and selfless contribution to the science field by some of its members have not gone unnoticed. The members including Michael N. Hall, Stephen J. Elledge, Alexander Varshavsky, and Bert Vogelstein were honored with the Breakthrough Prize in 2013.